

Harald Burkhardt

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5392313/harald-burkhardt-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57
papers

2,749
citations

22
h-index

52
g-index

61
ext. papers

3,228
ext. citations

4.9
avg, IF

4.15
L-index

#	Paper	IF	Citations
57	Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany.. <i>Rheumatology Advances in Practice</i> , 2022 , 6, rkac002	1.1	1
56	Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). <i>Rheumatology</i> , 2021 , 60, 5318-5328	3.9	1
55	Genetic Analysis of MPO Variants in Four Psoriasis Subtypes in Patients from Germany. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 2079-2083	4.3	2
54	Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab. <i>Medicine (United States)</i> , 2020 , 99, e20201	1.8	2
53	Genetic variants in FBLIM1 gene do not contribute to SAPHO syndrome and chronic recurrent multifocal osteomyelitis in typical patient groups. <i>BMC Medical Genetics</i> , 2020 , 21, 102	2.1	5
52	Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study. <i>Clinical Rheumatology</i> , 2020 , 39, 2583-2592	3.9	1
51	Cell-Type Targeted NF-kappaB Inhibition for the Treatment of Inflammatory Diseases. <i>Cells</i> , 2020 , 9,	7.9	13
50	Individual therapeutic DAS28-d responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies. <i>Rheumatology International</i> , 2020 , 40, 747-755	3.6	
49	Rare Loss-of-Function Mutation in SERPINA3 in Generalized Pustular Psoriasis. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 1451-1455.e13	4.3	22
48	Innovative Imaging Technique for Visualization of Vascularization and Established Methods for Detection of Musculoskeletal Inflammation in Psoriasis Patients. <i>Frontiers in Medicine</i> , 2020 , 7, 468	4.9	1
47	IL-38 Ameliorates Skin Inflammation and Limits IL-17 Production from T _H Cells. <i>Cell Reports</i> , 2019 , 27, 835-846.e5	10.6	44
46	Analyses of association of psoriatic arthritis and psoriasis vulgaris with functional NCF1 variants. <i>Rheumatology</i> , 2019 , 58, 915-917	3.9	4
45	ADAM15 in Apoptosis Resistance of Synovial Fibroblasts: Converting Fas/CD95 Death Signals Into the Activation of Prosurvival Pathways by Calmodulin Recruitment. <i>Arthritis and Rheumatology</i> , 2019 , 71, 63-72	9.5	3
44	Use of a "critical difference" statistical criterion improves the predictive utility of the Health Assessment Questionnaire-Disability Index score in patients with rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019 , 3, 51	2.9	5
43	The sneaking ligand approach for cell type-specific modulation of intracellular signalling pathways. <i>Clinical Immunology</i> , 2018 , 186, 14-20	9	1
42	Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab. <i>Rheumatology</i> , 2018 , 57, 1938-1946	3.9	3
41	Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting. <i>Arthritis Research and Therapy</i> , 2018 , 20, 1	5.7	22

40	Cell adhesion-induced transient interaction of ADAM15 with poly(A) binding protein at the cell membrane colocalizes with mRNA translation. <i>PLoS ONE</i> , 2018 , 13, e0203847	3.7	1
39	Mannan-induced Nos2 in macrophages enhances IL-17-driven psoriatic arthritis by innate lymphocytes. <i>Science Advances</i> , 2018 , 4, eaas9864	14.3	18
38	GM-CSF in murine psoriasiform dermatitis: Redundant and pathogenic roles uncovered by antibody-induced neutralization and genetic deficiency. <i>PLoS ONE</i> , 2017 , 12, e0182646	3.7	9
37	Genome-wide association and targeted analysis of copy number variants with psoriatic arthritis in German patients. <i>BMC Medical Genetics</i> , 2017 , 18, 92	2.1	6
36	Replication of a distinct psoriatic arthritis risk variant at the IL23R locus. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1417-8	2.4	5
35	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814
34	Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study. <i>Journal of Rheumatology</i> , 2016 , 43, 632-9	4.1	21
33	Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis. <i>Rheumatology</i> , 2016 , 55, 1791-5	3.9	20
32	Association of Improvement in Pain With Therapeutic Response as Determined by Individual Improvement Criteria in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 1607-1615	4.7	9
31	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015 , 6, 6046	17.4	103
30	MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1058-64	2.4	106
29	Palmoplantar Pustular Psoriasis Is Associated with Missense Variants in CARD14, but Not with Loss-of-Function Mutations in IL36RN in European Patients. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 2538-2541	4.3	57
28	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1882-5	2.4	49
27	The "sneaking-ligand" approach: cell-type specific inhibition of the classical NF- κ B pathway. <i>Methods in Molecular Biology</i> , 2015 , 1280, 559-78	1.4	5
26	Sneaking-ligand fusion proteins attenuate serum transfer arthritis by endothelium-targeted NF- κ B inhibition. <i>Methods in Molecular Biology</i> , 2015 , 1280, 579-91	1.4	7
25	Identification of new citrulline-specific autoantibodies, which bind to human arthritic cartilage, by mass spectrometric analysis of citrullinated type II collagen. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1440-9	9.5	42
24	Development and validation of a new disease activity score in 28 joints-based treatment response criterion for rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2013 , 65, 1608-16	4.7	8
23	NF- κ B inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF- κ B in immune-mediated diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 16556-61	11.5	56

22	ADAM15 adds to apoptosis resistance of synovial fibroblasts by modulating focal adhesion kinase signaling. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2826-34		17
21	ADAM15 protein amplifies focal adhesion kinase phosphorylation under genotoxic stress conditions. <i>Journal of Biological Chemistry</i> , 2012 , 287, 21214-23	5.4	11
20	Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locus. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3801-6		22
19	Crystal structure of an arthritogenic anticollagen immune complex. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3740-8		22
18	Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. <i>Immunological Reviews</i> , 2010 , 233, 9-33	11.3	75
17	Visualization and phenotyping of proinflammatory antigen-specific T cells during collagen-induced arthritis in a mouse with a fixed collagen type II-specific transgenic T-cell receptor β chain. <i>Arthritis Research and Therapy</i> , 2010 , 12, R155	5.7	4
16	ADAM15 exerts an antiapoptotic effect on osteoarthritic chondrocytes via up-regulation of the X-linked inhibitor of apoptosis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1372-82		24
15	ADAM15 modulates outside-in signalling in chondrocyte-matrix interactions. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 2634-2644	5.6	11
14	Collagen type II is recognized by a pathogenic antibody through germline encoded structures. <i>European Journal of Immunology</i> , 2008 , 38, 2784-95	6.1	13
13	TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2056-64		76
12	Association between protein tyrosine phosphatase 22 variant R620W in conjunction with the HLA-DRB1 shared epitope and humoral autoimmunity to an immunodominant epitope of cartilage-specific type II collagen in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006 , 54, 82-9		33
11	Lack of evidence for genetic association to RUNX1 binding site at PSORS2 in different German psoriasis cohorts. <i>Journal of Investigative Dermatology</i> , 2005 , 124, 107-10	4.3	21
10	Systematic linkage disequilibrium analysis of SLC12A8 at PSORS5 confirms a role in susceptibility to psoriasis vulgaris. <i>Journal of Investigative Dermatology</i> , 2005 , 125, 906-12	4.3	34
9	Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. <i>European Journal of Immunology</i> , 2005 , 35, 1643-52	6.1	164
8	Homeostatic effects of the metalloproteinase disintegrin ADAM15 in degenerative cartilage remodeling. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1100-9		49
7	Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2339-48		125
6	Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 9960-5	11.5	346
5	Highly enhanced expression of the disintegrin metalloproteinase MDC15 (metargidin) in rheumatoid synovial tissue. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2046-54		32

- | | | | |
|---|--|-----|----|
| 4 | Cartilage-specific autoimmunity in rheumatoid arthritis: characterization of a triple helical B cell epitope in the integrin-binding-domain of collagen type II. <i>European Journal of Immunology</i> , 2001 , 31, 1666-73 | 6.1 | 30 |
| 3 | Up-regulation of MDC15 (metargidin) messenger RNA in human osteoarthritic cartilage. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1946-50 | | 40 |
| 2 | Arthritis-related B cell epitopes in collagen II are conformation-dependent and sterically privileged in accessible sites of cartilage collagen fibrils. <i>Journal of Biological Chemistry</i> , 1998 , 273, 1551-61 | 5.4 | 71 |
| 1 | Macrophages, but not dendritic cells, present collagen to T cells. <i>European Journal of Immunology</i> , 1995 , 25, 2234-41 | 6.1 | 62 |